Kim. And morning Thank you, everyone. good
And for their whom Joining Khursheed Science on questions our normally first me Church, us us I'd vacation call. with well-deserved a us. Celsion's financials. provide us is Dr. LHA Celsion's so also Chief colleagues Chief Anwer, today Golodetz who won't to calls quarterly Jeffrey and during will to of Nick with Officer, be a call. with today the Medical for welcome like he available Officer, be of the joins the Officer, both call Kim who Chief review Financial are will Dr. for Borys,
know to that our bring LHA and IR engaged interactions are with I looking recently community. the forward they partners investment our to have will the as value that We
ThermoDox, be clinical that a a now it's with of to of development through will always, on our milestones have immunotherapy. we pleasure and elegant GEN-X key as rigorous our close execution programs we you gene-mediated in tumor-targeting particularly chemotherapy achieved speaking As
strong and quarters expected For several quarters I've stronger even report in reported with of events and this can now I third fourth the fundamentals are our year. that key
All milestones beyond clinical support will in to our one programs. XXXX. major cover the his the sufficient an more runway well of Well these report. Jeff into during cash is detail financials operating
remarks, themes Now important of as my to I of begin like you formal the make company. aware I'd
to are to like I'd achieve objectives. say First, our again, we well-positioned
We few technology have them have to the the capital deliver we and to personnel, years. the as past the resources, over relationships, continue the the been
advance Our promised. development programs to as continuing clinical
reading Our X patient of will global year. Phase study begin XXX this out in October
Phase First by X the data year. from the end our of study I/II OVATION
the our the matter taken be have ThermoDox margins impressive robust to lead no the product supply local Gross chains two or ensure We and will economy. cost-efficient necessary steps for for candidates. market
gene-mediated will costs Our candidates enjoy ensure product a have fraction competitive going multiple future. cost and plasmid-based product Both continuity options small of immunotherapy supply at drugs. the of sourcing into to on other
net stock taken and and financing gets. million operating more is on And short with adding million $X warrants nothing to short prepaid hedge have past a that. with you only the common investor-friendly. virtually cash to ensure initiatives trade clean been very With of New little sheet, structure capitalization Jersey our expenses Our in We closed balance million agree or it We've hope no consider dilution the we sale the if over two in of forward you leverage will as to losses. as look we this $XX quarter $XX our I years, steps through over another position.
see to the key drivers XX months. next than enough through value more our cash have We us over
fields by their Thaker opinion for key continue potential it's all the for patients recent the the cancer this or leaders known. ovarian to science, ThermoDox dramatic announcing Premal and of cancer by medicine witnessed to primary and talk leaders of Dr. HCC and GEN-X promise garner as the of addition or support -- we press in In regarding liver given hepatocellular our global carcinoma releases
carefully As at and review their researchers by described HEAT of XXX-patient Study the our independent data. NIH
be and not could We confident. more pleased
because So we much call, right, writing HCC. if in have I what are could well-positioned to we begun soon told important last deliver we have oncology and generation. a may so NDA be medicines in you that not conference ThermoDox new the Frankly, our the began as for started writing we enough among most we're
second were ThermoDox both number programs. that demonstrate highlighted in our The by recent and GEN-X development with announcements of quarter weeks progress
in in of plan agreed to the with that study announced diagnosed evaluating our trial radiofrequency August in a of One interim Phase disclosed our is of minutes Xth, reached patients. events our the for RFA or of off in with was our we from news pieces HCC combination in when to also FDA. HCC. first first statistical we significant had XX of pre-specified standardized analysis newly ThermoDox treatment-naive ablation, necessary of X minimum allow as most This OPTIMA But number known important data the
reach successful A ratio approximate the this design. XX% X.XX or interim the observed represents X.XXX. over of an optimist X.XXXX first XXX number of final that which in consistent study hazard locked to assessment or improvement like and on range plan. XX% database we is survival analysis for again, for successful. order immediate deaths the our be in was for within control necessary at which the of trial with be the XXX The ratio analysis to X.XXX the the arm. statistical XX% and hazard subgroup to trial higher agreed deaths ratio to a hazard is of I'd slightly a that that saw represents the study And number has HEAT deaths, in Say improvement we largely conduct prospect XXX than the in to based deaths minimum total XXX of is a required in the the note this provides to
So know if a there's that I translate of can information. I lot
in of survival to at the the than for successful design bit the median we We interim trial was to just of base study used in that to better in have saw analysis the group OPTIMA first this do us order be trial. a prospect terms subgroup, for little on
So the trial's or call DMC as independent we meet end the it the interim review data the October monitoring before committee to data. will of
study lower ratio the for was arm, to represents recommendations that necessary announce X.XX approximate conducted At success. in deaths. see, will has interim after to expect possible review, If be death of for the their reached interim a as We XX% a the median is X.XX much at not the thereafter. this control A threshold analysis which the a success ratio has pre-specified XXX for success as greater to study compare threshold can the for second you data soon over as which hazard this hazard analysis, potential it the based success represents you time an on. when first improvement
So to reiterate our previous for want analysis. I guidance interim the first
to number probability improves While first it be is patients study the of possible interim, for the declared successful evaluated. with of success the at OPTIMA
interim we DMC interim death the achieve of the current rate optimistic a XXXX positive to October in that expected population. accelerated first meeting success trial remain we're analysis, occur the the second and trial for which at analysis, at likelihood recommend the assuming we study is the is FDA unblinding the in of Should ratio with in to half hazard much greater either will the While request reserved seeing the of approval.
from the reminder, a XXX-patient cancer. markets in OPTIMA study I XX is study. said, as on Now fully prospect countries. XXX study from with in and primary enrolled Doctor's based August clinical the a for represent Those the countries XX each from XXXX sites -- subjects, each world subgroup all study of group as was liver major
is a or survival median demonstrate more I repeat this years is with prospective this, been identified combine of a And followed when then again repeat control to perspective, combination minutes other alone. of they this X patients who who short more Different treated I nothing than minutes I conference with standardized a or overall plus-minus of in in we for study we more be at We RFA minutes, remarkable. ThermoDox the of them ThermoDox. determine who And survival. XX to I'll benefit every group call. In with of And RFA those And patients benefit. of critical RFA X.X ThermoDox. XX we they improve minutes of subgroups, than say the for clear. are XX years than XX received survival with of had survival I say an treated evaluation to saw that's standardized want hope two that's metric RFA what than identified RFA heating more to years more
significant and hope that out it, Tuesday's suggests their cause not you request, points you on the As The The that An of Institutes you the do. if independent our optimistic. Health National to haven't press analysis some read we will. have from HEAT resulted time of Tuesday, a was procedure XXth, confirmed results announced for at conducted be NIH's suggest request, release improvement I heating I request. of publication study it the This analysis of ThermoDox increasing the this statistically the entire from past overall August data and has in that analysis. we set RFA performed in survival. the an
evaluation peer-reviewed Journal included and Interventional data of from with online lesions. all The the the Now single survival in Radiology. NIH's journal patients Vascular --
XXX So the with that That with use was amount population. all lesion. they lesions almost the study XX% patients radiofrequency of could of because specificity determine tumors patients, representing retreated the They single time ablation. single
point appears arm survival in XX the inflection X.X tumor equal that design two earlier, established trial greater median increasing the years different as from the two to heating I Imagine a the be This of -- for is some for if results. of heating improvement convincing time more what which never of have minutes death two XX I and that. a do is evaluated the told milliliter is still associated times, with follow that and than analysis per Independently years. that's tumor. full way, after patient's the finding it. some the Which of XX% hope data look, it's you case, years, you than the but minutes three-centimeter own if an benefit the mitigating improves arm to a risk presented time substantially volume about is XXX with control set is math, over company's of half of over when tumor. we of consistent the In versus of out control tumor largely survival turns tumor. This the alive three-centimeter patients concluding reached. minutes are patients, it with
launch. with parallel In commercial this we for everything putting in manufacturing are product evaluation, trial place and
our for manufacturers be late United States, I'm modules. that three have And a GAAP meeting We've the nothing China. we with in of that ThermoDox, like The missing. the We've pre-clinical there when two the we manufacturing letter. thing know will conducted in meeting for the sure what a August. in already want CMC you file set As we last pre-NDA complete is do review make the analysis. response to NDA a one USFDA We'd calling is we date in
proactively So company very acting in this your regard. is
We as to previous I'd be call. will also meeting conference in you mentioned
the regulatory in formerly strategy discuss planning in to authorities. for So this the ThermoDox Chinese China. formerly quarter NMTA with filing That's the meeting third for we're meeting CFDA the our SFDA. the We're
the meeting only are or great have the you surgically recent interest long new As can that year able in means periods. China, astounding. benefit them from I chemoembolization, to And this every in RFA diagnosed and these not potential cycles with with the data recovery patients ThermoDox of understand pharmacoeconomics our given clinical pharmacy finding review. the the nothing has data are Many have of short long mentioned multiple study, expressed their accelerate but for cases which require most which earlier, significant for XXX,XXX -- over and plus to be are a authorities hospitalization of impatience treated to Chinese
procedure. the in an ThermoDox, many in future, you be In As an past, can even overnight procedure. in I cases, the plus some told outpatient hospitals RFA
Another and point exceeds The on. then and I going worldwide. again just want commercial yesterday, model opportunity reviewed billion to we're this dollars reiterate our a conservative move we to by
Asia and annually in here in with world, here, XX% patients every more in of of HCC. patients are is the and and just HCC including EMA key pointed -- NIH U.S. the and Chinese. annually in incidence HCC cases Some the to die X% To the few out annually. is significant, I agency disease. cases and XX,XXX mortality new is FDA you. statistics increasing XX,XXX XXX,XXX XXX,XXX Approximately in other HCC approximately CDC from this on are minds Europe. cancer The the than others, China diagnosed by of health certainly
So -- give world. the the for The the is I ThermoDox you in the HCC leading what's third So future mean here? what's hepatitis I'm successful, HCC let's one major C. are death what to cause B factors and statistic. risk going -- is summary assume And of
a A with major B Approximately are patients liver C. infected billion worldwide one-third for cancer. of risk hepatitis factor or primary
So and say for that be we're it a addressing therapeutic that patients. confidence, with studies a that need in clearly, hopes we're the these provide can -- pressing changing way, medical me outcomes so the conducting let significant that that will
tumor as be could data And So an -- let's excited. told summarize. primary you where is for liver valuable very before, exceptional more generated which immediately as successful there's exceptionally evaluate this we're we've potential believe channels. other ThermoDox, assuming will HCC. we're in solid just other which, to I've for seen success solid some and indications asset, cancer, turn very, We for
while and believe we interest of compelling gene-based GEN-X investors, to that are equally folks ThermoDox is immunotherapy. promise focus in and great investors’ so the and And for some immediate OPTIMA holds
to of Agilent development, X the These in Phase in know, cancer We're effects. are combination what cocktail planetary treated and medicine this some have treatment-naive and GEN-X elegant prior is Early you chemotherapy, evaluated very is know and very cytokines is which mediated study study. taking amino with that I/II outcomes though, improve X chemotherapeutics therapeutic. X diagnosed late-stage as potent goal The protein the patients. called surgery, surgical newly to stage GEN-X recognized -- of RILPLG evaluating in OVATION you being ovarian standard This with care, side delay is of progression. science of with anti-cancer GEN-X to the serious immunotherapeutic. approach and a to a
a and presented The particularly Huntsville administration has over little -- our very which show direction from Anwer a Dr. times. therapeutic, a from developed of X multiple that ago. has been completed in Our data promise studies under trial was year great which showing scientists this early safe local is for our Phase
always We want to concerned say is about safety. gene therapeutic
completed and there's Oncology of this demonstrated Again, trials have A in study. We clinical activity, five mean, cancer. I it's suggest been it. question on ovarian Safety is Future virtually unequivocal. XXXX. in it. in read GEN-X published biological you no in Much It's every I October available about website. was our
describes immune our for potential was platform, it's administered the of it as profile to us from to makes many, synthetic, nanoparticles system, many which of be article this the delivery the creates our over importantly, not ideal produce a its seen the of only cycles transport we've in vector, attracted therapist candidate and safety a immunotherapy. an interleukin that without but what The it that interference levels this evaluations, pharmacies bio for therapeutic non-viral that XX. beauty these plasmid While is cells technology
treated of and XXX% we this surgical two from being nonetheless, data of quarter at remind cohorts at relative X but zero Xb highest OVATION in X from reported And the top resection first a will were cohorts, patients -- very the rate compelling A you highest Phase who study, I'll the had the is final response we had trial. near-term of hopefully [ph]. its study data the manuscript line. And treated be saw an compelling objective study the the year, way, by in During small finalized two score. highest published R X the patients
and comes operating expected significant and improvement and patient. overall and the of next layman's in the in all. all I R patient's it to tissue translated goes not it's removed the survival. got from the the predictive means of I kin is these zero when terms PFS out zero surgeon says he diseased patients of of Now he of room
All Dr. in the marked months increased in treated of shift Institute PDLX supports in improvement PFS Together data us -- I multiple representing be the the the of and of all importantly, which direction would PDX, We Roswell from among of medium evaluated particularly And both the to including literature components tumor months some saw -- immunotherapy, biomarkers, under impressive ovarian innate immunosuppressive was in increasing XX patients XX area across the XX supported at with literature remarkable activity saw think Repasky for we anti-cancer a KOL by and -- months of and progression others. XX% immune a Repasky Cancer provided cancer translational micro-environment. significant us immune according this. expected the of so that the very protocol. with historical cancer. reduction adaptive system. to to this this Park across demonstrate in data activity XX
try shift So understand I level the immune this system, I'm tumor from I'm an hides and an immunologist it immunologist, in gets is the is a This for. what not to community lethal immunology that malignant looking But nicely to to not that micro-environment this that as mass. would. a the very going foothold the become convince to itself you
We've translational very our to I/II moved study advisors. recommendation a of about clinical data we're at So supporting the the Phase excited data.
in we're Phase two a the trial difficult We're decentralized XX the at XX along startup, with and that. a therapies the and cetera. XX to to sites changes after first now in XX Phase process delighted in which review trials any early by to we've year-end. expect committees, X talked had some enrolled of X a trial have sites. into a review, to scientific by many of took from sites Phase to That study recruiting moving The year sites. report we direction. next Overall OVATION portion we We centralized some review In trial study the et which review I about -- we next due NIH have this promised. have end the is have X active in year complete the establish. fully at through enrollment calling a XXX portion study cohorts by momentum event, approval over reported patients goal running in largely patient gene-based to as of We about as year for it X our very The
study sites that the in recall, of is ensure the trial September ensure had higher the goal We of trial XX enrollment to you DSMV meet here XX first but will to we somewhat If a cohort designed on created was on then originally with complete sites. that evaluate cost basis. the a to The timely we patients. the
cohort as the rolling be second begin patients. will We'll as completed soon okay. is The DMC
expect and evaluated We the the objective and response by cohort outcomes second of the enrolled have for year. to end surgical
first for XXX of So per to a its we'll we've are GEN-X efficacy enrolling excited to really one I the X to dose ThermoDox one and to said is when determine control this -- the milligrams compared trial. in XXXX. so early have a for square, XXX-patient candidate compared randomized portion mean we It's meter begin trial arm. arm achieved to the This we'll as time control begin Phase I again, evaluate
be These after patients maintenance therapy receiving also will surgery. a
overall recurrence, as survival to to immediate direct because cancer goal impact prevent recruit to link Our recurrence this survival. the improving immune is know a a continue we progression-free of on the system and
They in in not we to more meeting the earlier reported, could regarding our breakthrough successful, suggested Once with The be year, established therapy meeting the we supportive that trial accelerate -- interested study, accelerating indicated Phase As which from our in it do. with one the data of to we the and face report spoke FDA with the once develop and program. small asked would X my this in is and my and a the interest of development FDA to management randomized it exchanges to been our combine opinion, FDA X have our consideration I team we study in the so scientists data X plan us potentially also face that to they our OVATION most career. productive breakthrough FDA development discuss Phase dose to choose. the the for the portion the if our designs subset, submit
regard. and GEN-X that we're So with interest in excited the cancer. very IL-XX And in FDA's ovarian
of data potential investment optimistic to followed the your released and Under for that PFS. remain as after even we'd of will primary will will been -- is whichever for conducted us, open-label OVATION the as fully disclosed enrolling And analysis the XXXX is after at can that For patients be this have [indiscernible] treatment the by execution program. so XX evaluated the the but done for so here judgment available Phase clinical have cancer. X make at to design, of patients released by study's progression-free trial We available its endpoint like as months, completed the least more from that. being progressed be survival primary this We've least place you of on to it's investigators. the it study. study be That XX XX community in X patients GEN-X overall, soon later. find data ovarian the throughout make that the We've all it's study will
for both this to our that or I patients Mr. our has fundamentals Celsion quarter I second very and I at over over of Jeff? call the a for studies before turn our that, we rates, access want that can for to -- community. now deep in turn later Underpinning So this my transformative our to with take call financial either will reasonable comments. medical to a for reasonable very expect balance and our to the And review capital significant And continue you clinical potential of From hope Church. Jeff economics announcements. see to year. I is emphasize results, strong sheet. to value the to shareholders, create have breath
